

ANNEX II
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

CARTON BOX

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Prasequine 1 mg tablets

2. STATEMENT OF ACTIVE SUBSTANCES

Pergolide 1.0 mg (equivalent to 1.31 mg pergolide mesilate)

3. PACKAGE SIZE

60 tablets
91 tablets
100 tablets
160 tablets
240 tablets

4. TARGET SPECIES

Horses (non food-producing)

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Oral use.

7. WITHDRAWAL PERIODS

Withdrawal period:

Not authorised for use in horses intended for human consumption.

The horse must have been declared as not intended for human consumption under national horse passport legislation.

Not authorised for use in mares producing milk for human consumption.

8. EXPIRY DATE

Exp. {mm/yyyy}

9. SPECIAL STORAGE PRECAUTIONS

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

CP-Pharma Handelsgesellschaft mbH

14. MARKETING AUTHORISATION NUMBERS

Vm 20916/3002

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

OPA/aluminium/PVC-aluminium blisters

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Prasequine

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Pergolide 1.0 mg

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Prasequine 1 mg tablets for horses

2. Composition

Each tablet contains:

Active substance:

Pergolide 1.0 mg
equivalent to 1.31 mg pergolide mesilate

Excipients:

| Qualitative composition of excipients and other constituents |
|---|
| Lactose monohydrate |
| Croscarmellose sodium |
| Povidone |
| Magnesium stearate |
| Iron oxide yellow (E172) |

Off-white round and convex tablet with a cross-shaped break line on one side. Tablets can be divided into 2 or 4 equal parts.

3. Target species

Horses (non food-producing).

4. Indications for use

Symptomatic treatment of clinical signs associated with Pituitary Pars Intermedia Dysfunction (PPID) (Equine Cushing's Disease).

5. Contraindications

Do not use in horses with known hypersensitivity to pergolide mesilate or other ergot derivatives or to any of the excipients.
Do not use in horses less than 2 years of age.

6. Special warnings

Special warnings:

Appropriate endocrinologic laboratory tests should be conducted as well as evaluation of clinical signs in order to establish a diagnosis of PPID.

Special precautions for safe use in the target species:

As the majority of cases of PPID are diagnosed in aged horses, other pathological processes are frequently present. For monitoring and frequency of testing, see section 8.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

This veterinary medicinal product may cause eye irritation, an irritating smell, or headache after dividing the tablets. Avoid contact with the eyes and inhalation when handling the tablets. Minimise exposure risks when dividing or dissolving tablets, e.g. tablets should not be crushed.

In case of contact with skin, wash exposed skin with water. In the event of eye exposure, flush the affected eye immediately with water and seek medical advice. For nasal irritation, move to fresh air and seek for medical attention if breathing difficulty develops.

This veterinary medicinal product may cause hypersensitivity (allergy) reactions. People with known hypersensitivity to pergolide or other ergot derivatives should avoid contact with the veterinary medicinal product.

This veterinary medicinal product may cause adverse effects due to decreased prolactin levels, which poses a particular risk to pregnant and lactating women. Pregnant or lactating women should avoid dermal contact or hand-to-mouth contact by wearing gloves when administering the veterinary medicinal product.

Accidental ingestion, especially by children, may cause vomiting, dizziness, tiredness, or low blood pressure. To avoid accidental ingestion, carefully keep the veterinary medicinal product out of reach and sight of children. Tablet parts should be returned to the open blister space. Blisters should be inserted back into the outer packaging and kept in a safe place. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Do not eat, drink or smoke when using this veterinary medicinal product. Wash hands after use.

Pregnancy:

Use only according to the benefit/ risk assessment by the responsible veterinarian. The safety of this veterinary medicinal product has not been demonstrated in pregnant mares. Laboratory studies in mice and rabbits have not produced any evidence of teratogenic effects. Reduced fertility was seen in mice at a dose of 5.6 mg/kg body weight per day.

Lactation:

The use is not recommended in lactating horses, in which the safety of this veterinary medicinal product has not been demonstrated. In mice, reduced body weights and survival rates in the progeny were attributed to the pharmacological inhibition of prolactin secretion resulting in lactation failure.

Interaction with other medicinal products and other forms of interaction:

Use with caution in case the veterinary medicinal product is co-administered with other drugs known to affect protein binding.

Do not administer concurrently with dopamine antagonists, such as neuroleptics (phenothiazines - e.g. acepromazine), domperidone, or metoclopramide, as these agents may reduce the effectiveness of pergolide.

Overdose:
No information available.

7. Adverse events

Horses:

| | |
|--|--|
| Rare (1 to 10 animals / 10,000 animals treated): | Inappetence, transient anorexia and lethargy, mild central nervous system signs (e.g. mild depression and mild ataxia), diarrhoea and colic. |
| Very rare (<1 animal / 10,000 animals treated, including isolated reports): | Sweating. |

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to <the marketing authorisation holder> <the local representative of the marketing authorisation holder> using the contact details at the end of this leaflet, or via your national reporting system <{national system details}>.

8. Dosage for each species, routes and method of administration

Oral use, once daily.

Starting dose

The starting dose is about 2 µg pergolide/kg (dose range: 1.7 to 2.5 µg/kg; see table below). The maintenance dose should then be titrated according to the individual response as determined by monitoring (see below), resulting in an average maintenance dose of 2 µg pergolide/kg bodyweight with a dose range of 0.6 to 10 µg pergolide/kg bodyweight.

Starting doses are recommended as follows:

| Horse body weight kg | Number of tablets | Starting dose mg/horse | Dosage range µg/kg |
|-------------------------|----------------------|---------------------------|-----------------------|
| 200 - 300 | ½ | 0.50 | 1.7 – 2.5 |
| 301 – 400 | ¾ | 0.75 | 1.9 - 2.5 |
| 401 - 600 | 1 | 1.00 | 1.7 – 2.5 |
| 601 - 850 | 1 ½ | 1.50 | 1.8 – 2.5 |
| 851 - 1000 | 2 | 2.00 | 2.0 – 2.4 |

Maintenance dose

Lifelong treatment is anticipated for this disease.

Most horses respond to therapy and are stabilised at an average dose of 2 µg pergolide/kg body weight. Clinical improvement with pergolide is expected within 6 to 12 weeks. Horses may respond clinically at lower or varying doses; it is therefore recommended to titrate to the lowest effective dose per individual based on response

to therapy, whether it is effectiveness or signs of intolerance. Some horses may require doses as high as 10 µg pergolide/kg body weight per day. In these rare situations, appropriate additional monitoring is advised.

Following initial diagnosis, repeat endocrinologic testing for dose titration and monitoring of treatment at intervals of 4 to 6 weeks until stabilisation or improvement of clinical signs and/or diagnostic testing occurs.

If clinical signs or diagnostic testing have not yet improved at the first 4 to 6 week interval, the total daily dose may be increased by 0.25 - 0.50 mg. In case clinical signs have improved but are not yet normalised, the veterinarian may decide to titrate or not to titrate the dose, considering the individual's response/tolerance to the dose.


In case clinical signs are not adequately controlled (clinical evaluation and/or diagnostic testing) it is recommended to increase the total daily dose by 0.25 – 0.50 mg increments (if the drug is tolerated at that dose) every 4 to 6 weeks until stabilisation occurs.

If signs of dose intolerance develop, treatment should be stopped for 2 to 3 days and reinstated at one-half of the previous dose. The total daily dose may then be titrated back up to the desired clinical effect by 0.25 - 0.50 mg increments every 2 to 4 weeks.

If a dose is missed, the next scheduled dose should be administered as prescribed.

Following stabilisation, regular clinical assessment and diagnostic testing should be performed every 6 months to monitor treatment and dose. Where there is no apparent response to treatment, the diagnosis and/or treatment plan should be re-evaluated.

Tablets can be divided into 2 or 4 equal parts to ensure accurate dosing. Place the tablet on a flat surface, with its scored side facing up and the convex (rounded) side facing the surface.



2 equal parts: press down with your thumbs on both sides of the tablet.

4 equal parts: press down with your thumb in the middle of the tablet.

9. Advice on correct administration

To facilitate administration, the required daily dose should be placed in a small amount of water and/or mixed with molasses or other sweetener and agitated until dissolved. In this case, the dissolved tablets should be administered with a syringe. The whole amount should be administered immediately. Tablets should not be

crushed, see section 6. When tablets are divided, the remaining tablet portion should be given at the next administration.

10. Withdrawal periods

Not authorised for use in horses intended for human consumption.
The horse must have been declared as not intended for human consumption under national horse passport legislation.
Not authorised for use in mares producing milk for human consumption.

11. Special storage precautions

Keep out of the sight and reach of children.
This veterinary medicinal product does not require any special storage conditions.
Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the blister after EXP. The expiry date refers to the last day of that month.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater [or household waste].

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

UK(NI) only:

Medicines should not be disposed of via wastewater. Any unused veterinary medicinal product should be disposed of in accordance with local requirements.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

OPA/aluminium/PVC-aluminium blisters, containing 7 or 10 tablets each.
Carton box of 60, 91, 100, 160 or 240 tablets.
Not all pack sizes may be marketed.

Vm 20916/3002

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder and manufacturer responsible for batch release and contact details to report suspected adverse reactions:

CP-Pharma Handelsgesellschaft mbH
Ostlandring 13
31303 Burgdorf
Germany

Local representatives and contact details to report suspected adverse reactions:

Audevard
37-39 rue de Neuilly
92110 Clichy
France
pvrc@audevard.com
+33 1 47 56 38 26

17. Other information

Approved: 18 June 2024

Gavin Hall